#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Astrocytoma malignant Hyperoxaluria Breast cancer metastatic Neurodermatitis Malignant fibrous histiocytoma Hormone-dependent prostate cancer Paraganglion neoplasm Infective uveitis Proteus syndrome Hairy cell leukaemia recurrent Bone marrow disorder Extra-osseous Ewing's sarcoma Deafness Intracranial germ cell tumour Dementia Alzheimer's type More trials…

    Learn about Rare Diseases

    Combined immunodeficiency – Trials in Disease Metachromatic leukodystrophy – Treatment Congenital nephrogenic diabetes insipidus – Life with Disease Osteosarcoma – Life with Disease Pemphigoid – Trials in Disease Glomerulonephritis membranoproliferative Nephrotic syndrome Hepatic angiosarcoma – Trials in Disease Friedreich’s ataxia – Basic Information Small intestine leiomyosarcoma – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Mepivacaine Hydrochloride Daratumumab Albumin Peposertib Rbd4059 Delafloxacin Tamsulosin Hydrochloride Povidone, Iodinated Deutivacaftor Nafarelin Nirmatrelvir Norfloxacin Capmatinib Biotin Agrostis Stolonifera Pollen Cefepime Hydrochloride Pyridoxine Aminocaproic Acid Duvakitug Human Fibrinogen More therapies…

    Learn about Your Condition

    Cytomegalovirus infection Pulmonary resection Haemofiltration Erosive oesophagitis Frontotemporal dementia Senile dementia Mantle cell lymphoma stage IV Fracture infection Progressive supranuclear palsy Meningioma Aortic aneurysm Endocrine ophthalmopathy Hyperthyroidism Neurodegenerative disorder Mixed-type liposarcoma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Waldenstrom’s macroglobulinaemia

  • Study of CLR 131 for Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia
    Investigated Drugs:
    • 18-(P-Iodophenyl)Octadecyl Phosphocholine
    • Levothyroxine Sodium
    • Potassium Iodide
    France Greece Spain

  • Study on Brexucabtagene Autoleucel for Adults with Relapsed/Refractory Waldenstrom Macroglobulinemia Using a Drug Combination

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia
    • Waldenstrom’s macroglobulinaemia refractory
    Investigated Drugs:
    • Anhydrous Cyclophosphamide
    • Betamethasone Sodium Phosphate Ph. Eur
    • Brexucabtagene Autoleucel
    Austria France Germany Italy The Netherlands Spain +1

  • Long-Term Safety Study of Venetoclax for Patients with Chronic Lymphocytic Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Acute Leukemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia
    • Chronic lymphocytic leukaemia
    • Plasma cell myeloma
    Investigated Drugs:
    • Venetoclax
    Belgium Denmark France Greece Ireland Poland +1

  • Study on Carfilzomib and Ibrutinib for Patients with Waldenström’s Macroglobulinemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia
    Investigated Drugs:
    • Ibrutinib
    • Carfilzomib
    Austria Germany Greece

  • Study on the Effectiveness of Bortezomib, Rituximab, and Ibrutinib for Patients with Newly Diagnosed Waldenström’s Macroglobulinemia

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Waldenstrom’s macroglobulinaemia
    Investigated Drugs:
    • Ibrutinib
    • Bortezomib
    • Rituximab
    Germany Greece
Previous Page
1 2

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!